Director, Business Development – M&A
2 days ago
Egham
Our recent acquisition of Renaissance Pharmaceuticals is a significant milestone for Essential Pharma, the groups second product for treatment of a rare disease, and the first development-stage asset in our portfolio. In December 2024, Essential Pharma announced a €900 million recapitalisation wi...